Lantern Pharma is trading 5.5% up at $2.30 amid a broadly positive August 27, 2026 session.

  • The Nasdaq Composite is up 1.34%, while the S&P 500 is up 0.59%, supporting risk-on buying in growth and biotechnology names.
  • No new company-specific announcement or catalyst dated August 27 was identified.
  • Lantern’s latest major disclosure was its August 14 quarterly update.